Mechanisms and molecular characterization of relapsed/refractory neuroblastomas
Open Access
- 6 March 2025
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1555419
Abstract
Relapsed/refractory neuroblastoma is a type of malignant solid tumor with a very poor prognosis in children. Its pathogenesis is complex, involving multiple molecular pathways and genetic alterations. Recent studies have shown that MYCN amplification, ALK mutation, TERT promoter mutation, p53 pathway inactivation, and chromosomal instability are the key mechanisms and molecular characteristics of relapsed/refractory neuroblastoma. Precision treatment strategies targeting these molecular mechanisms have shown certain prospects in preclinical studies and clinical practice. This review focuses on the relevant mechanisms and molecular characteristics of relapsed/refractory neuroblastoma, explores its relationship with treatment response and clinical prognosis, and briefly introduces the current treatment strategies to provide a theoretical basis for the development of novel and personalized therapeutic regimens to improve the prognosis of children.Keywords
This publication has 91 references indexed in Scilit:
- Pyrimido[1,2-a]benzimidazoles as inhibitors of oncoproteins ubiquitin specific protease 5 and MYCN in the childhood cancer neuroblastomaBioorganic Chemistry, 2023
- Tumoral heterogeneity in neuroblastomaBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2022
- Telomerase-targeting compounds Imetelstat and 6-thio-dG act synergistically with chemotherapy in high-risk neuroblastoma modelsCellular Oncology, 2022
- Reversing the HDAC-inhibitor mediated metabolic escape in MYCN-amplified neuroblastomaBiomedicine & Pharmacotherapy, 2022
- Neuroblastoma Heterogeneity, Plasticity, and Emerging TherapiesCurrent Oncology Reports, 2022
- Deep analysis of neuroblastoma core regulatory circuitries using online databases and integrated bioinformatics shows their pan-cancer roles as prognostic predictorsDiscover Oncology, 2021
- Targeting the p53-MDM2 pathway for neuroblastoma therapy: Rays of hopeCancer Letters, 2020
- A perspective on the early days of RAS researchCancer and Metastasis Reviews, 2020
- Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) projectPediatric Blood & Cancer, 2019
- ALK Mutations Confer Differential Oncogenic Activation and Sensitivity to ALK Inhibition Therapy in NeuroblastomaCancer Cell, 2014